Teva Pharmaceutical Industries Limited (TEVA)'s Emrusolmin Gains FDA Fast Track for Multiple System Atrophy

In this article, we will be taking a look at the 12 Cheap Healthcare Stocks to Buy Now. Teva Pharmaceutical Industries Limited is one of them.

Teva Pharmaceutical Industries Limited (NYSE:TEVA), a global pharmaceutical company, continues its transition from a generics-focused firm to a biopharmaceutical leader. The company operates nine U.S. manufacturing sites and maintains a global supply chain across Canada, Europe, and Israel, making it the largest generic manufacturer in the U.S.

Teva Pharmaceutical Industries Limited (NYSE:TEVA)’s growth strategy emphasizes both specialty products and biopharmaceutical innovation. Key drivers include Austedo, expected to surpass $2.5 billion in sales by 2027, and Uzedy, projected at $200 million in 2025. The corporation is also advancing new launches, such as an ICS-SABA combination inhaler targeted for release before 2027 and olanzapine planned for Q4 2026. The business aims to achieve a 30% operating margin by 2027, alongside plans to launch 5 new biosimilars within the same timeframe. Among cheap healthcare stocks, TEVA stands out as it combines the stability of its generics base with the momentum of an expanding biopharma pipeline.

Highlighting its innovative pipeline, Teva Pharmaceutical Industries Limited (NYSE:TEVA)’s investigational drug emrusolmin (TEV-56286) received FDA Fast Track designation on September 9, 2025, for the treatment of Multiple System Atrophy (MSA), a rare neurodegenerative disorder. This designation supports accelerated development and regulatory review, underscoring the company’s commitment to high-value therapies for serious conditions.

While we acknowledge the potential of TEVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure. None.